Moreover, survival analysis findings indicated that PAAD patients in the high CD206 or CD163 protein expression groups exhibited shorter survival times compared to the low expression group, although this difference was not statistically significant for CD163 (Figures 1I, J). This evidence concerns the gene CD163 and pancreatic adenocarcinoma.